Inappropriate Prescription in Elderly and Polypharmacy Patients in Primary Care (PHARM-PC) Trial (PHARM-PC)
Pharmacist-led Intervention to Reduce Potentially Inappropriate Prescription in Elderly and Polypharmacy Patients at Primary Care Setting (PHARM-PC) Cluster Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Main objective:
To assess the effect of Pharmaceutical Intervention (PI) on PIP in elderly patients with polypharmacy in PC.
Secondary objectives:
2. a. Assess baseline characteristics of elderly polypharmacy patients in PC; and assess association with the possible presence of PIP.
2. b. Describe the main types and the reasons for PIP. 3. Assess impact of PI on health outcomes (morbidity and mortality). 4. Estimate the effect of IF on the cost of both drugs and healthcare resources.
Design and methods:
Prospective, multicenter, open-label, controlled and randomized by groups (clusters) clinical trail; in order to prevent contamination between Intervention Group (IG) and Control Group (CG) patients seen by the same physician.
Clusters (unit of randomization) are primary care physicians who work in public primary care health centers in Tramuntana Sector (under Hospital Comarcal de Inca). Different cluster were randomly assigned to Intervention Group (IG) or control group (CG) in the ratio 1: 1.
The study compared the effectiveness of a strategy for health care to elderly patients with polypharmacy in PC consisting of medical visit along with PI, consistent in turn on identifying PIP and delivering therapeutic appropriateness recommendations against routine health care, consisting solely of medical visit.
Furthermore the impact of treatment on health outcomes, and both drug and health service costs will also be assessed.
Methodology:
Intervention Group:
Systematic review of treatments:
* Identification of reasons for PPI: Causes why a pharmacological prescription (drug, dose, route of administration, duration of treatment) may have both risk-benefit balance as cost-effectiveness balance unfavorable versus other alternatives, such as:
- contraindications, dosage (dose, frequency, duration, inappropriate), duplication, interactions, risk of adverse effects, health problem insufficiently treated, unnecessary medication; equivalent to Drug-Related Problems (DRP) listed in the Third Consensus of Granada. To identify DRP we will use a combination of explicit criteria (STOPP / START) and implicit criteria (information from: drug labels, drug-surveillance alerts issued by drug regulatory agencies, recommendations of scientific societies); implemented in CheckTheMeds® software.
Drugs that have more cost-effective alternatives, ranked by the Committee on Quality Indicators Prescription Health Service of the Balearic Islands as:
- New drugs with little or no therapeutic value: drugs marketed in the past 5 years and considered by the "Comité Mixto de Evaluación de Nuevos Medicamentos" as little or no therapeutic value against the alternatives available in the market for the treatment of these pathologies: metformin / saxagliptin, linagliptin / metformin, saxagliptin, linagliptin, rosuvastatin, pitavastatin, sinecatequin, ingenol mebutate, bazedoxifene, silodosin, degarelix, denosumab, hydromorphone, tapentadol, agomelatine, desvenlafaxine, indacaterol, ciclesonide, aclidinium bromide, glycopyrronium bromide, roflumilast, bilastine, tafluprost.
- Medications considered first choice in the treatment of the most prevalent diseases in the outpatient setting: Omeprazole (antiulcer); Metformin (oral antidiabetic); ACE inhibitors; Beta-blockers; diuretics; Calcium-antagonists (anti-hypertensive); Simvastatin (statins); diclofenac; Diclofenac / Misoprostol; ibuprofen; Naproxen (anti-inflammatory drugs); Alendronic acid (osteoporosis); fluoxetine; citalopram; paroxetine; Sertraline (antidepressant).
- Determination of recommended pharmacotherapeutic alternatives.
- Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine; discontinue medicine; adjust dosage; replace medicine.
- After the medical visit (the next day): New treatment review for: checking acceptance or rejection of the recommendations issued; and review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP.
Control Group: In the control group, the same steps will be followed than intervention group; excluding issue recommendations for therapeutic appropriateness to the doctor.
Sample size and statistical power:
The sample size was calculated by comparing proportions using the application for the determination of sample size available on Fisterra website; based on the results of a pilot study, not yet published, which showed a difference of 15 percent in the number of patients with PIP between IG and CG and based on the study by Delgado et al, which considers cost effective any screening tool that achieves at least a moderate reduction (10-20 percent) of PIP. For a power of 80%, and assuming a loss rate of 10 percent; was obtained a sample size of 153. Considering adjustment for cluster effect, according to the following formula: 1 + (m - 1) x ρ, we obtain a final sample size of 214 patients.
Statistics:
- Categorical variables (qualitative): Measurements of frequency and percentage. The association between categorical variables will be performed by chi-square or Fischer's exact test; accordingly.
- Continuous Variables (Quantitative): Measures of central tendency and dispersion measures. The association between continuous variables will be performed using T-Student t test; ANOVA; Mann-Whitney or Kruskal-Wallis, as appropriate.
A value of p ≤ 0.05 as statistically significant will be considered.
Timescale:
The study will begin in October 2014 and will end about April 2016. Is expected than patients will be enrolled into the study between October 2014 and April 2015, until complete sample size required.
The study will last 12 more months to assess the outcomes of morbidity, mortality and cost of health care resources
Ethics and safety:
The Research Ethics Committee and Primary Care Research Unit of Balearic Islands have approved the project.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baleares
-
Inca, Baleares, Spain, 07300
- Sector Sanitario Tramuntana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥ 65 years
- treatment with 5 or more chronic medications.
Exclusion Criteria:
- routine monitoring is carried out in private health care
- temporary displaced persons (routine monitoring is carried out in another community).
- Institutionalized patients
- Patients in the Home Care Program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
|
Systematic review of treatments: Identification of reasons for PPI.
After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP. |
|
No Intervention: Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with potentially inappropriate prescriptions (PIP)
Time Frame: Up to 6 months
|
This variable will be measured six months after intervention, when a new review of patient treatment will be performed to check acceptance by the physician of the recommendations issued by the pharmacist. PIP: Prescription (drug, dose, frequency of administration) that meets at least one of the following conditions: contraindication, inadequate dosing (dose, frequency and / or duration), duplication, interactions, probability of adverse drug reactions, health problem insufficiently treated, unnecessary medication; new drugs of little-no therapeutic value, drug which is not considered as first choice in the treatment of the most prevalent diseases in the outpatient setting. |
Up to 6 months
|
|
Mean number of PIP per patient
Time Frame: Up to 6 months
|
This variable will be measured six months after intervention, when a new review of patient treatment will be performed to check acceptance by the physician of the recommendations issued by the pharmacist.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morbidity
Time Frame: Up to 12 months
|
Composite end-point:
|
Up to 12 months
|
|
Total spending on drugs
Time Frame: Up to 6 months
|
Total monetary amount (in euros) of the drugs involved in the PIP; which is calculated as annual amount (being chronic medications), for which we will consider the invoice price (monetary amount paid by the health administration for drugs) specified in the pharmaceutical sales database from Balearic Islands and total daily dose prescribed. This variable will be measured six months after intervention (same timeline as primary outcome), when a new review of patient treatment will be performed to check acceptance by the physician of the recommendations issued by the pharmacist. |
Up to 6 months
|
|
Total spending on health resources.
Time Frame: Up to 12 months
|
Composite end-point: Total monetary amount (in euros) of the following health resources used due to PIP:
|
Up to 12 months
|
|
Mortality
Time Frame: Up to 12 months
|
Number of patients who died
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jesús Martínez, Pharm D, Hospital Comarcal de Inca
Publications and helpful links
General Publications
- Simo Minana J. [Use of prescription drugs in Spain and Europe]. Aten Primaria. 2012 Jun;44(6):335-47. doi: 10.1016/j.aprim.2011.06.009. Epub 2011 Oct 22. Spanish.
- Hill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013 Oct;38(5):360-72. doi: 10.1111/jcpt.12059. Epub 2013 Apr 2.
- Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83. doi: 10.5414/cpp46072.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PHARM-PC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.